


<!DOCTYPE html>
<html lang="en">
<head><script>(function (w, d, s, l, i) {
 w[l] = w[l] || []; w[l].push({
  'gtm.start':
  new Date().getTime(), event: 'gtm.js'
 }); var f = d.getElementsByTagName(s)[0],
 j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
 'https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
})(window, document, 'script', 'dataLayerCIT', 'GTM-W6MJHWF');</script>
	<meta charset="utf-8">
	<meta http-equiv="X-UA-Compatible" content="IE=edge">
	<meta name="viewport" content="width=device-width, initial-scale=1">
	<meta name="description" content="Explore SANDOSTATIN&#174; LAR Depot (octreotide acetate) for injectable suspension, a somatostatin analogue for acromegaly. See full Prescribing &amp; Safety Info.
" />
	<meta name="keywords" />
	<meta name="format-detection" content="telephone=no">
	<meta name="viewport" content="width=device-width, minimum-scale=1.0, maximum-scale=1.0, user-scalable=no">

	<title>SANDOSTATIN&#174; LAR Depot (octreotide acetate) for Acromegaly | HCP</title>

		<script language="javascript" type="text/javascript" src="http://www.pharma.us.novartis.com/privacy-lightbox/privacy-update-controller.js"></script>
		<script>



			var displayGlobalPPDisclaimer = false;
		</script>


	<link href="../../../bundles/css/master%3Fv=DFPHbovhUMiL9Dn52heMUNXymBxWvano9tAsQ64HmSY1.css" rel="stylesheet"/>

	<script src="../../../bundles/script/jquery%3Fv=4Fx6N4x0ohHzU3HBQJk1GtgRoUo_IXc-CWFU9ADPAB81"></script>



	


  <!-- V4 JS core and at least one video plugin is required. Plugins such as skin, discovery and Advertising need to be loaded separately -->
  <script src="http://player.ooyala.com/static/v4/stable/4.8.5/core.min.js"></script>
  <script src="http://player.ooyala.com/static/v4/stable/4.8.5/video-plugin/main_html5.min.js"></script>
  <script src="http://player.ooyala.com/static/v4/stable/4.8.5/video-plugin/osmf_flash.min.js"></script>
  <!-- Change these html5-skin.min.css and html5-skin.min.js to your local build if necessary -->
  <script src="http://player.ooyala.com/static/v4/stable/4.8.5/skin-plugin/html5-skin.min.js"></script>
  <link rel="stylesheet" href="http://player.ooyala.com/static/v4/stable/4.8.5/skin-plugin/html5-skin.min.css" />



 <link href="../../../bundles/css/brands%3Fv=MJ1cSwv0ph-T8cA6caKmdNsA7L_OcnSUI801YYiuxLo1.css" rel="stylesheet"/>


  <style type="text/css">
.brandColor, .left-teaser a{
 color:#19a2b1;
}
a.brandColor,
a.brandColor:hover,
a.brandColor:active
{
 color:#19a2b1;
}
.brandBackColor {
 background-color:#19a2b1;
}
.select-indication a.brandColor {
 color: #19a2b1;
}
.select-indication li:hover a.brandColor {
 color: #19a2b1;
}
  </style>



		




		<script>
			window.dataLayerOnco = window.dataLayerOnco || [];

			var preDataLayerOnco = {"environment":"STAGE","department":undefined,"indication":"acromegaly","brand":"sandostatin-lar-depot","type":undefined,"sectionLevel1":"products","sectionLevel2":"acromegaly","sectionLevel3":undefined,"status":undefined,"name":"products : sandostatin-lar-depot : acromegaly"};
			preDataLayerOnco.department = 'oncology';
			preDataLayerOnco.type = 'hcp';
			preDataLayerOnco.status = 200;
			dataLayerOnco.push({
				'page':preDataLayerOnco
			});
		</script>
		<!-- Google Tag Manager -->
		<script>
(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
		new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
		j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
		'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
		})(window,document,'script','dataLayerOnco','GTM-PH7LL77');</script>
		<!-- End Google Tag Manager -->


</head>
<body>

		<!-- Google Tag Manager -->
		<noscript>
			<iframe src="https://www.googletagmanager.com/ns.html?id=GTM-PH7LL77" height="0" width="0" style="display:none;visibility:hidden"></iframe>
		</noscript>
		<!-- End Google Tag Manager -->

	<script type="text/javascript">

  $(document).ready(function () {

/**/
// global vars
var path = window.location.pathname.split('/'),
pageName,
channel,
brandProduct,
campaign;

/**/
// URL / dataLayer functions
function getQueryVariable(variable) {
 var query = window.location.search.substring(1);
 var vars = query.split('&');
 for (var i = 0; i < vars.length; i++) {
  var pair = vars[i].split('=');
  if (decodeURIComponent(pair[0]) == variable) {
return decodeURIComponent(pair[1]);
  } else {
return "";
  }
 }
}

function dataLayerFunction() {
 $('a').not('#brand-detail-page .uso-tab-menu a').not('.onePageTemplatePage .uso-tab-menu a').on('click', function () {
  var $this = $(this);
  if ($this.parents('.selectpicker').length == 0) {

var pattern = /^.*\.(docx|DOCX|xlsx|XLSX|xls|doc|DOC|pdf|PDF)$/;
if ($this.attr('href') !== undefined) {
 var ext = $this.attr('href').match(pattern);

 if (ext != null) {
  if (ext[1] == 'docx' || 'DOCX' || 'xlsx' || 'XLSX' || 'xls' || 'doc' || 'DOC' || 'pdf' || 'PDF') {
fileDownload = $this.attr('href');
dataLayer.page.fileDownload = fileDownload;
  }
 }
}
  }
 })

 $('.research-landing-page a').on('click', exitLink);
 $('#uso-product-page a').on('click', exitLink)
 function exitLink() {
					var href = $(this).attr('href');
					if (typeof href != 'undefined') {
						var boolExternalLink = isExternalLink(href);
						if (boolExternalLink) {
							dataLayer.page.exitLink = href;
						}
					}
 }
 function isExternalLink(href) {
  var dataTarget = $(this).data('target');
  var domain = href.split("?");
  if (domain[0].indexOf('http') != -1 && domain[0].indexOf(window.location.hostname) == -1 && dataTarget != "none") {
return true;
  } else {
return false;
  }
 }
}

/**/
// set dataLayer vars
if (path.length == 2) {
 pageName = "home";
 channel = "";
} else {

 var hasEndSlash = (window.location.pathname.lastIndexOf('/') == window.location.pathname.length - 1);
 if (hasEndSlash) {
  if (path[path.length - 1] == "") {
path.pop();
  }
 }
 path = path.slice(1);
 pageName = path.join(':').toLowerCase();
 if (path.length == 1) {
  channel = pageName;
 } else {
  channel = path[0];
 }
}
// sets the last url location value to brandProduct
brandProduct = window.location.pathname.split('/');
brandProduct = brandProduct[brandProduct.length - 2];
if (brandProduct == "")
 brandProduct = "home";

campaign = getQueryVariable("site");

dataLayerFunction();

/**/
// build dataLayer
dataLayer = {
 page: {
  pageName: 'hcp' + ':' + pageName,
  channel: channel,
  pageCategory: 'HCP',
  eVar20: brandProduct,
  campaign: campaign
 }
};

  });
	</script>
	<main>
				



		
		<a href="http://usoncohcp-web.stage.novartis.episerverhosting.com/"></a>
		<a href="http://usoncohcp-web.stage.novartis.episerverhosting.com/"></a>
		
		<a href="http://localhost:38015/"></a>
		<a href="http://localhost:38015/"></a>
		
		<a href="http://localhost:38015/?link=hgjhgjhg"></a>
		<a href="http://localhost:38015/?link=hgjhgjhg"></a>

		<div id="movingOnDisclaimer" class="modal fade" data-backdrop="static">
			<div class="modal-dialog">
				<div class="modal-content">
					<div class="modal-header">
						<button type="button" class="close" data-dismiss="modal" aria-label="Close"><span aria-hidden="true">&times;</span></button>
						<img class="center-block" src="../../../Static/img/global/uso-logo-header.png" />
					</div>
					<div class="modal-body">

						<p>
							We’re moving on!<br />
							Join us at <span data-dismiss="modal" class="hcpLink">www.hcp.novartis.com</span>—our new location for health care professionals to find product, access, and medical information. Now you can find the tools you need to help manage your patients, all in one place!
						</p>
						<p>You’ll have access to the site in a moment, or click <span class="hcpLink" data-dismiss="modal">continue</span> to  close this message and advance directly to the site.</p>

					</div>
					<div class="modal-footer">
						<div class="disclaimer-omap">
							12/15 ONC-1130276
						</div>
					</div>
				</div>
			</div>
		</div>

		<div id="uso-page">
			
			<div><div>


<div class="container-fluid container-header">
 <nav class="navbar navbar-default">
  <div class="uso-mobile-nav-header visible-xs-block visible-sm-block visible-md-block">This site is for US health care professionals only.</div>

  <div style="position:relative;">
<div id="uso-mobile-search-block">
 <input id="uso-mobile-search-input" type="text" class="uso-search-header-mobile clearable" placeholder="Search" />
</div>
<div class="navbar-header  ">
 <div class="navbar-toggle collapsed" data-toggle="collapse" data-target="#navbar" aria-expanded="false" aria-controls="navbar" data-link="/">
  <span class="sr-only">Toggle navigation</span>
  <img class="uso-nrts-logo" src="../../../globalassets/novartis_logo_2016_.png" alt="Novartis logo" />
 </div>
 <a class="navbar-brand visible-lg-block visible-lg-block" href="http://usoncohcp-admin.stage.novartis.episerverhosting.com/" title="Novartis logo"><img class="uso-nrts-logo" src="../../../globalassets/novartis_logo_2016_.png" alt="Novartis logo" /></a>
	
					<div class="tagline">
						<span class="uso-navbar-brand-desc visible-lg-inline-block">This site is for US health care professionals only.</span>
					</div>

  <div id="uso-brandheader-mobile-menu" class="hidden-lg">
<nav class="navbar-collapse bs-navbar-collapse collapse" aria-expanded="false">
  <p class="uso-brandheader-indication">For: Acromegaly</p>
 <ul class="nav navbar-nav">
 </ul>
</nav>
  </div>
		</div>
 </div>
</nav>
</div>
<input id="uso-hidden-search-page-url" type="hidden" value="/search/" /></div></div>
			





<div class="container">
 <div class="row brandHeader">
  <div class="col-lg-6 col-md-6 col-xs-12" title="Sandostatin&#174; LAR Depot (octreotide acetate) for injectable suspension logo">
<a class="backLink" href="../index.html" title="Sandostatin&#174; LAR Depot (octreotide acetate) for injectable suspension logo"><i class="fa fa-angle-left"></i></a>
<img class="brandLogo" src="../../../globalassets/products/sandostatin-lar/sandostatin-header-logo-2019-01-24.png" alt="Sandostatin&#174; LAR Depot (octreotide acetate) for injectable suspension logo" />
  </div>
<div class="col-lg-6 col-md-6 col-xs-12 indicationsSelector clearfix">
 <b>For:</b>

 <div id="selector-container">
  <div class="current-indication">
<span>Acromegaly</span>
  </div>
  <ul class="select-indication">

  <li class=""><a class="" href="../carcinoid-syndrome/index.html" target="_self" data-target="none">Severe Diarrhea and Flushing Associated With Carcinoid Syndrome</a></li>
  </ul>
 </div>
</div>

 </div>
</div>
<div class="container-fluid">
 <div class="row rowIsi ">
  <div class="col-lg-12 isiLinkContainer brandBackColor">
 <a href="index.html#important-safety-info" class="isiLink arrow" >
IMPORTANT SAFETY INFORMATION AND INDICATION </a>
  </div>
 </div>
 
</div>


<div id="brandLandingPage" class="container-fluid brand-container onePageTemplatePage">
 <div class="container">
  <div class="row mainContent">
<div class="col-teasers teasers-col ">
  <div class="teasers-sticky">
<div class='left-teaser'>



<div class="quick-links-teaser clearfix">
  <h3 class="brandColor hidden-xs hidden-sm">Quick Links</h3>
 <ul>
<li class="info"><a title="Prescribing Info" href="https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/sandostatin_lar.pdf" target="_blank" rel="nofollow" data-target="none">Prescribing Info<br /></a></li>
<li class="link"><a title="Visit Patient Site" href="https://www.us.sandostatin.com/acromegaly" target="_blank" rel="nofollow" data-target="none">Visit Patient Site</a></li>
</ul>
</div>
</div>
<div class='left-teaser'>

<div class="quick-info-teaser-ISI">
 <div>
<strong class="brandColor">Important Safety Information</strong>

<div class="content">
 <p><strong>Warnings and Precautions</strong> Gallbladder abnormalities may occur. There have been postmarketing reports of cholelithiasis (gallstones) resulting in complications, including cholecystitis, cholangitis, ...</p>
</div>

  <a href="index.html#important-safety-info" class="isiLink isiLinkSUB">
<strong class="brandColor">See More</strong>
  </a>
 </div>
</div>




</div>

  </div>
 <div class="teasers">
<div class='left-teaser'>

<div class="quick-info-teaser-block-indication">

<p><strong class="brandColor">Indication</strong> Sandostatin<sup>®</sup> LAR Depot (octreotide acetate) for injectable suspension is indicated for long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors and long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors in patients in whom initial treatment with immediate-release Sandostatin<sup>®</sup> (octreotide acetate) Injection has been shown to be effective and tolerated. In patients with carcinoid syndrome and VIPomas, the effect of Sandostatin Injection and Sandostatin LAR Depot on tumor size, rate of growth, and development of metastases has not been determined.</p>
</div>
</div>

 </div>
</div>


<div class="col-content content-col">
 <div class="row rowLeftContent">
  <div class="uso-brand-detail-main">
<div class="row">
 <div class="col-lg-12">
  <h1  class="hidden-xs hidden-sm brandColor">Acromegaly</h1>
<ul class='uso-tab-menu clearfix'>
</ul>

 </div>
</div>
  </div>
  <div class="row row-banner">
<div class="col-lg-12" title="Sandostatin LAR Depot (octreotide acetate for injectable suspension)" >
 <div class="uso-brand-landing-banner">
<div class="resizingResponsive uso-brand-hero">
 <img class="desktop" src="../../../globalassets/products/sandostatin-lar/one-page-website/sandostatinlarhcp-bg1.jpg" />
  <img class="desktop1" src="../../../globalassets/products/sandostatin-lar/one-page-website/sandostatinlarhcp-bg1.jpg" />
 <div class="uso-banner-text">
  <div style="color:">

  </div>
 </div>
</div>
 </div>
</div>
  </div>
  <div class="uso-brand-detail-main">
<div class="row">
 <div class="col-lg-12">
  <div class="uso-brand-details"><div class="uso-brand-detailcontent">
<div class="uso-cpyblk-content">
 <h3 class="brandColor">The right support at the right time</h3>
<ul class="brand-detail-copy-block-liste">
<ul style="margin-bottom: 0;">
<li>The single source for patient and caregiver support</li>
<li>Financial assistance option to help patients get access to the treatment(s) they need</li>
<li>Personalized 1-on-1 support through unique programs designed to work with patients when they’re needed most</li>
</ul>
</ul>
<p>To learn more about what the Novartis Oncology Patient Support Program can offer your patients, call 1-800-282-7630 or visit <strong><a href="https://www.hcp.novartis.com/access/">www.HCP.Novartis.com/Access/</a></strong>.</p>
</div></div><div class="uso-brand-detailcontent">
<div class="uso-cpyblk-content">
 <h3 class="brandColor">Mobile Administration Program:</h3>
<p>When caring for patients who are receiving Sandostatin<sup>®</sup>&nbsp;LAR Depot (octreotide acetate for injectable suspension) therapy, you know how important it is to administer injections exactly as prescribed. But you also know that it's not always easy for some of your patients to get to the office to receive their injections by a trained health care provider.</p>
<p>The Sandostatin Mobile Administration Program&nbsp;is not intended to replace the care provided by you and your office,&nbsp;but to help eligible patients receive their injections on schedule at home or at a location convenient to them, by a trained health care professional. Through this program, you will receive regular patient reports, to keep you up to date on your patients' receipt of Sandostatin&nbsp;LAR Depot injections.</p>
<p><strong>Which patients are eligible?</strong></p>
<p>The MAP is an additional benefit for all appropriate and eligible patients with acromegaly for whom Sandostatin&nbsp;LAR Depot has been prescribed.</p>
<ul>
<li>Patients must be recommended by their physician</li>
<li>Residents of all states except Massachusetts, Michigan, Minnesota, and Rhode Island can participate</li>
<li>The program is available to patients covered by most commercial plans (HMO, PPO, etc)</li>
<li>Patients with government-provided medical insurance (eg, Medicare Part B and D, or Medicaid) are not eligible</li>
</ul>
<p>Your office can confirm patient eligibility easily by calling 1-877-503-3377 and speaking with a representative. You can also print the enrollment form by clicking&nbsp;<a href="https://www.hcp.novartis.com/access/" target="_blank">here</a>.</p>
<p><strong>Advantages of the MAP</strong></p>
<p>Because the program provides specially trained registered nurses, you can feel confident about the following:</p>
<ul>
<li>No guesswork. You know that your patient will receive the right dose, at the right time, using the right technique</li>
<li>Feedback from registered nurses. The nurse will submit a detailed report to you after each visit. You will know when the patient receives his/her treatment at the prescribed dose</li>
<li>Your patients can receive injections when it is convenient for their schedule. Nurses are available outside traditional office hours, including weekends and evenings, even when patients are traveling within the continental United States</li>
<li>Time saved for your patient. Your patient won't need to make long trips to the treatment center</li>
<li>Nurse handles all needle disposals. The program nurse handles disposal of all equipment</li>
<ul>
<li><strong>The MAP program is not intended to replace the care provided by a patient's health care team</strong></li>
</ul>
</ul>
<p><strong>How MAP works</strong></p>
<ul>
<li>As the prescribing physician, you evaluate your patients on a case-by-case basis and decide who is appropriate for the program</li>
<li>Your office submits the patient's information to the company that administers the program, in one of two ways:</li>
<ul>
<li>By calling 1-877-503-3377 or</li>
<li>By completing and sending in the&nbsp;<a title="Enrollment form" href="https://www.hcp.novartis.com/access/" target="_blank">enrollment form</a></li>
</ul>
<li>Patient eligibility is verified according to your patient's insurance plan</li>
<li>Your patient receives a call to schedule the next injection at the patient's schedule. (Patients must receive their first dose of Sandostatin LAR Depot in your office)</li>
<li>A specially trained treatment nurse visits your patient's home and:</li>
<ul>
<li><em><strong>Administers</strong></em> the injection</li>
<li><strong><em>Schedules</em></strong> the next appointment and follows up with a reminder</li>
<li><strong><em>Sends</em></strong> a report to you, the prescribing physician, to update you on the patient’s status</li>
</ul>
</ul>
<p><strong>Important things to note about the MAP</strong></p>
<ul>
<li>The program does&nbsp;<em>not</em>&nbsp;replace your care or the authority of the prescribing physician. It simply provides your patients with the convenience of home injections. Patients still keep their regular, scheduled physician checkups</li>
<li>Patients must receive their first dose of Sandostatin&nbsp;LAR Depot in your office</li>
<li>Nurses who take part in this program are specially trained to mix and administer Sandostatin&nbsp;LAR Depot</li>
</ul>
</div></div></div>
 </div>
</div>
  </div>
 </div>
</div>
<div class="col-isi-content ">
<div class=" row">
  <div class="">
<a name="important-safety-info" class="internalAnchor"></a>
<p class="brandColor"><strong>SANDOSTATIN<sup>®</sup>&nbsp;LAR Depot</strong></p>
<p><strong class="brandColor">Indication and Usage</strong></p>
<p>Sandostatin<sup>®</sup> LAR Depot (octreotide acetate) for injectable suspension is indicated for patients in whom initial treatment with immediate-release Sandostatin<sup>®</sup> (octreotide acetate) Injection has been shown to be effective and tolerated for long-term maintenance therapy in acromegalic patients who have had inadequate response to surgery and/or radiotherapy or for whom surgery and/or radiotherapy is not an option (the goal of treatment in acromegaly is to reduce GH and IGF-1 levels to normal).</p>
<p class="brandColor"><strong>IMPORTANT SAFETY INFORMATION</strong></p>
<p><strong>Warnings and Precautions</strong></p>
<ul>
<li>Gallbladder abnormalities may occur. There have been postmarketing reports of cholelithiasis (gallstones) resulting in complications, including cholecystitis, cholangitis, pancreatitis, and requiring cholecystectomy in patients taking Sandostatin LAR Depot. Patients should be monitored periodically. If complications of cholelithiasis are suspected, discontinue Sandostatin LAR Depot and treat appropriately</li>
<li>Glucose Metabolism: Hypoglycemia or hyperglycemia may occur. Blood glucose levels should be monitored when Sandostatin LAR Depot treatment is initiated or when the dose is altered. Antidiabetic treatment should be adjusted accordingly</li>
<li>Thyroid Function: Hypothyroidism may occur. Baseline and periodic assessment of thyroid function (TSH, total and/or free T4) is recommended</li>
<li>Cardiac Function: Bradycardia, arrhythmia, conduction abnormalities, and other ECG changes may occur. The relationship of these events to octreotide acetate is not established because many of these patients have underlying cardiac disease. Use with caution in at-risk patients</li>
<li>Nutrition: Octreotide may alter absorption of dietary fats. Monitoring of vitamin B<sub>12</sub> levels is recommended during therapy with Sandostatin LAR Depot. Patients on total parenteral nutrition (TPN) and octreotide should have periodic monitoring of zinc levels</li>
</ul>
<p><strong>Drug Interactions</strong></p>
<ul>
<li>The following drugs require monitoring and possible dose adjustment when used with Sandostatin LAR Depot: cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine. Octreotide has been associated with alterations in nutrient absorption, so it may have an effect on absorption of orally administered drugs. Drugs mainly metabolized by CYP3A4 and which have a low therapeutic index should be used with caution</li>
</ul>
<p><strong>Adverse Reactions</strong></p>
<ul>
<li>The most common adverse reactions occurring in patients receiving Sandostatin LAR Depot were biliary abnormalities (52%), diarrhea (36%-48%), cholelithiasis (13%-38%), abdominal pain or discomfort (11%-29%), flatulence (26%), influenza-like symptoms (20%), constipation (19%), headache (15%), anemia (15%), hyperglycemia (15%), injection-site pain (2%-14%), hypertension (13%), dizziness (12%), fatigue (11%), nausea (10%), vomiting (7%), hypothyroidism (2%), hypoglycemia (2%), and goiter (2%)</li>
</ul>
<p><strong>Please see&nbsp;full <a href="https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/sandostatin_lar.pdf" target="_blank">Prescribing&nbsp;Information</a>.</strong></p>
  </div>
 </div>
</div>
  </div>
 </div>
</div>

		</div>
		<div class="container-fluid">
			<div class="row">
				<div>
					<div class="uso-back-to-top hidden-lg text-center">
						<a href="index.html#" onclick="scrollWinTop()"><img src="../../../Static/img/global/uso-icon-back-to-top.png" /></a> <br />
						<a href="index.html#" onclick="scrollWinTop()" class="uso-btt-link">BACK TO TOP</a>
					</div>
					<div class="uso-back-to-top-lg hidden"></div>
				</div>
			</div>
		</div>
	</main>
	<div><div>
<div style="" class="stop-sticky container-fluid uso-footer">
 <div class="container">
  <div class="row">
<div class="col-lg-12 text-center">
 <div class="uso-ftr-social">
  
  
 </div>
 <div class="uso-ftr-links">
  <p><a class="btn btn-link" href="https://medinfo.novartispharmaceuticals.com/" target="_blank" rel="nofollow" data-target="none">Medical Information</a>&nbsp;<span class="divider">|</span>&nbsp;<a class="btn btn-link" href="https://www.hcp.novartis.com/contact" target="_blank" rel="nofollow" data-target="none">Contact Us</a>&nbsp;<span class="divider">|</span>&nbsp;<a class="btn btn-link" href="http://www.sandostatin.com/?non-us" target="_blank" rel="nofollow" data-target="none">Non-US Residents</a></p>

 </div>
</div>
  </div>
  <div class="row">
 
<div class="col-lg-6 text-left center-tablet-phone">
 <div class="uso-ftr-logo">
  <a href="https://www.novartis.us/about-us" title="Novartis Oncology" target="_blank" data-target="none"><img src="../../../globalassets/novartis-logo-111516.svg" alt="Novartis Oncology"></a>
 </div>
</div>
  </div>

  <div class="row">
<div class="col-lg-12 text-left center-tablet-phone">
 <div class="uso-ftr-disclaimer">
  <p>Use of website is governed by the&nbsp;<strong><a class="btn btn-link" href="https://www.novartis.us/terms-use" target="_blank" rel="nofollow" data-target="none">Terms of Use</a></strong>&nbsp;and&nbsp;<strong><a class="btn btn-link" href="https://www.novartis.us/hcp-privacy-policy" target="_blank" rel="nofollow" data-target="none">Privacy Policy</a></strong>.</p>
 </div>
 
</div>
  </div>
  <div class="row">
<div class="col-lg-6 col-xs-12 text-left center-tablet-phone">
 <div class="uso-ftr-copyright">
  <p>Copyright © 2020 <a class="btn btn-link" href="https://www.pharma.us.novartis.com/about-us" target="_blank" rel="nofollow" data-target="none">Novartis Pharmaceuticals Corporation</a>. All rights reserved.</p>
 </div>
</div>

<div class="col-lg-6 col-xs-12 text-right center-tablet-phone">
 <div class="uso-ftr-code">
  5/19 SDA-1212502
 </div>
</div>
  </div>
 </div>
</div>

<div id="termsOfuseModal" class="modal fade">
 <div class="modal-dialog">
  <div class="modal-content">
<div class="modal-body">
 
</div>
  </div>
 </div>
</div>

<div id="privacyPolicyModal" class="modal fade">
 <div class="modal-dialog">
  <div class="modal-content">
<div class="modal-body">
 
</div>
  </div>
 </div>
</div></div></div>

	<script src="../../../bundles/script/master%3Fv=IgwyWqHAVMW8mZv43JHre8PsGfwvmO76Tt124V1TBDo1"></script>


	
 <script src="../../../bundles/script/brands%3Fv=35NHaC3i5xK1MiMzsewDx66lvpjLyMB4aSozWPFmjmg1"></script>



	<script>
		function scrollWinTop() {
			$(window).scrollTo(0, 500);
			return false;
		}
	</script>
	<div class="container">
		<a href="index.html#" id="uso-sticky-back"><i class="fa fa-angle-up"></i></a>
	</div>



				<div id="interstitialPopUp" class="modal fade">
					<div class="modal-dialog">
						<div class="modal-content">
							<div class="modal-header">
								<button type="button" class="close" data-dismiss="modal" aria-label="Close"><span aria-hidden="true">&times;</span></button>
								<img class="center-block novartis-logo" src="../../../Static/img/global/Novartis-Logo.svg" />
							</div>
							<div class="modal-body">
								<p>You are now leaving the Novartis site and moving to an external website independently operated and not managed by Novartis Pharmaceuticals Corporation. Novartis assumes no responsibility for the site. If you do not wish to leave this site, click Cancel. Or click OK to continue.</p>
							</div>
							<div class="modal-footer">
								<div class="text-center">
									<a class="btn btn-default btn-cancel" data-dismiss="modal"><span>Cancel</span></a>
									<a class="btn btn-continue interstitialOKButton" id="" href="index.html#">OK</a>
								</div>
									<div class="disclaimer-omap">
										1/17  ONC-1154329
									</div>
							</div>
						</div>
					</div>
				</div>


		
</body>





</html>
